DAPA VILDA 10/100 SR

Description

Dapagliflozin and Vildagliptin DAPA VILDA 10/100 SR is a specially formulated oral antidiabetic medication that combines Dapagliflozin (10 mg) and Vildagliptin (100 mg) in a sustained-release (SR) form. This innovative combination is prescribed to improve glycemic control in adults with type 2 diabetes mellitus (T2DM), particularly when diet and exercise alone are not sufficient. Dapagliflozin is a SGLT2 inhibitor that helps reduce blood glucose by promoting the excretion of excess sugar through urine. It also has additional benefits like reducing weight and lowering blood pressure in some patients. Vildagliptin is a DPP-4 inhibitor that enhances incretin hormone activity, thereby increasing insulin secretion and reducing glucagon release in a glucose-dependent manner. Together, this dual mechanism provides better blood sugar control, cardiovascular support, and improved long-term diabetes management. Uses of DAPA VILDA 10/100 SR This medicine is primarily used in the treatment and management of type 2 diabetes mellitus. The main uses include: Improving glycemic control in patients with T2DM. Used as dual therapy when metformin alone is insufficient or in patients intolerant to metformin. Helps in reducing HbA1c levels effectively. May aid in weight reduction and blood pressure management due to dapagliflozin’s unique mechanism. Reduces the risk of diabetes-related complications, such as heart disease, kidney issues, and nerve damage, when combined with proper diet and exercise. Side Effects of DAPA VILDA 10/100 SR While generally well tolerated, some patients may experience mild to moderate side effects. These include: Common side effects: Urinary tract infections (UTIs) Genital fungal infections Increased urination Headache Dizziness or fatigue Gastrointestinal discomfort (nausea, diarrhea, abdominal pain) Less common but serious side effects: Hypoglycemia (when combined with insulin or sulfonylureas) Dehydration and low blood pressure (due to increased urination) Rare cases of pancreatitis with DPP-4 inhibitors Rare allergic reactions such as rash, itching, or swelling If any severe reactions occur, medical assistance should be sought immediately. Precautions Before Using DAPA VILDA 10/100 SR Patients should consider the following precautions before starting therapy: Kidney and liver health: Avoid use in patients with severe renal impairment or advanced liver disease. Hydration: Maintain adequate fluid intake to reduce the risk of dehydration and low blood pressure. Infections: Dapagliflozin increases the risk of genital infections; good personal hygiene is recommended. Hypoglycemia risk: More likely if taken with insulin or sulfonylureas—dose adjustment may be required. Pregnancy and breastfeeding: Use only if clearly prescribed by a doctor. Surgery or hospital admission: Inform the healthcare provider, as temporary discontinuation may be required. Lifestyle: This medicine should always be combined with dietary changes, exercise, and weight management for best outcomes. Drug Interactions DAPA VILDA 10/100 SR may interact with certain medications: Insulin and sulfonylureas: Increase the risk of low blood sugar. Diuretics: May enhance the dehydration and hypotensive effect of dapagliflozin. Other antidiabetic drugs: Caution required to avoid excessive glucose lowering. CYP enzyme-modifying drugs: Some medicines may alter the metabolism of vildagliptin. Blood pressure-lowering medications: Combined effect may increase the risk of dizziness or fainting. Always inform your healthcare provider about all medicines, supplements, or herbal products being used before starting this therapy. Conclusion DAPA VILDA 10/100 SR (Dapagliflozin and Vildagliptin SR) is an effective and modern therapy for the management of type 2 diabetes mellitus. By combining two complementary mechanisms—glucose excretion through urine and enhanced insulin release with reduced glucagon activity—this medicine offers comprehensive control over blood sugar levels while providing added benefits such as potential weight loss and blood pressure regulation.